SURVYR

PCVX

Vaxcyte, Inc.
$63.62
−$1.65 (2.53%)Oct 16 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-9%+10%+29%+49%+68%Oct 2025Oct 2026Apr 202652w low $39.87
PCVXSPY
Wall St. Highest PT $163.00 (+156.2%) Wall St. Avg PT $117.30 (+84.4%)
$40$72$104$136$168POC $56Hi $163Avg $117
Underwater Drawdown %Max DD -28.0%Current -13.8%
0.0%-28.0%
Relative Strength vs SPY+28.8% vs SPYOutperforming
+58%0%-58%
1W
−$7.76 (10.87%)
1M
+$4.85 (8.25%)
3M
+$7.42 (13.20%)
6M
+$1.27 (2.04%)
YTD
+$17.48 (37.88%)
1Y
+$20.03 (45.95%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
11 analysts · mean score 1.27
1 = Strong Buy · 5 = Sell
Strong Buy19%
Buy982%
Hold19%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$63.62
Average target$117.30
+$53.68 (+84.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$75.00
Median$121.00
High$163.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-12 · Cantor Fitzgerald reiterated Overweight on PCVX
Reiterated
2026-10-05 · BTIG reiterated Buy on PCVX
Reiterated
2026-10-05 · Needham reiterated Buy on PCVX
Reiterated
2026-10-05 · Guggenheim reiterated Buy on PCVX
Reiterated
2026-09-28 · B of A Securities reiterated Buy on PCVX
Reiterated
2026-09-25 · Needham reiterated Buy on PCVX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$9.5B
P/E (next 12 months, estimated)-8.5
52-week range$39.87 – $90.75
Dividend yieldNo dividend
Analyst consensusStrong Buy (10)
Average analyst price target$117.30 (+84%)

What they do

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for PCVX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

PCVX earningsNext report in 7 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Time not confirmed
EPS consensus-$2.11 range -$2.68–-$1.67
Revenue consensus$0 9 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$1.97est -$2.10+6.1%Above estimates
May 6, 2026-$2.30est -$1.77−29.6%Below estimates
Feb 24, 2026-$1.80est -$1.50−19.7%Below estimates
Nov 4, 2025-$1.56est -$1.24−26.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 09:04:37 ET
24-1125-0225-0525-0825-1126-0226-0526-08-2.300.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
Zacks · Oct 14
BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push
Stocktwits · Oct 09
Vaxcyte Closes Offerings of Common Stock, Warrants, and Senior Notes
MT Newswires · Oct 09
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
GlobeNewswire · Oct 09
Sector Update: Healthcare
MT Newswires · Oct 09
Rating changes
Reiterated
2026-10-12 · Cantor Fitzgerald reiterated Overweight on PCVX
Reiterated
2026-10-05 · BTIG reiterated Buy on PCVX
Reiterated
2026-10-05 · Needham reiterated Buy on PCVX
Reiterated
2026-10-05 · Guggenheim reiterated Buy on PCVX
Reiterated
2026-09-28 · B of A Securities reiterated Buy on PCVX
Reiterated
2026-09-25 · Needham reiterated Buy on PCVX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-25 09:04:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026